Logo

Human Genome Sciences Q1 Revenue Shrivels as R&D Costs Surge

Apr 15, 2002

NEW YORK, April 15 - Human Genome Sciences said today that poor income from collaborations caused first-quarter revenue to plummet to $600,000 from $5.3 million during the same period last year.

The company also reported a widened net loss, which came in at $38.3 million, or $.30 per share in the current quarter, from $13 million, or $.10 per share, year over year.

R&D spending jumped to $45.6 million from $32.1 million, HGS said.

 

The company has scheduled a conference call for 1:00 p.m. Eastern time today.

Breaking News
The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.